CRISPR Therapeutics Announces European Patent for CRISPR/Cas …GlobeNewswire (press release)BASEL, Switzerland, March 28, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP) reported that the European Patent Office (EPO) has …and more&nb… Continue reading
Medical XpressPioneering stem cell gene therapy cures infants with bubble baby diseaseMedical XpressUCLA researchers have developed a stem cell gene therapy cure for babies born with adenosine deaminase-deficient severe combined immunodeficiency, a rar… Continue reading
Medical XpressPioneering stem cell gene therapy cures infants with bubble baby diseaseMedical XpressUCLA researchers have developed a stem cell gene therapy cure for babies born with adenosine deaminase-deficient severe combined immunodeficiency, a rar… Continue reading
Endpoints News |
Bristol-Myers Squibb (BMY), CRI, and Parker Institute for Cancer …
StreetInsider.com Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. The Parker Institute for Cancer Immunotherapy, … Parker Institute, BMS, and CRI Partner on Immuno-Oncology ResearchGenetic Engineering & Biotechnology News BMS seeks leg-up in immuno-oncology with Parker Institute and CRI pactFierceBiotech |
Endpoints News |
A gene therapy pioneer moves from Biogen to Regenxbio, staying focused on gene therapy 2.0
Endpoints News Olivier Danos’ arrival as head of Biogen’s gene therapy group two-and-a-half years ago signaled an important shift in the big biotech’s R&D focus. In swift order Biogen executed a partnership with the San Raffaele-Telethon Institute for Gene Therapy … Regenxbio (RGNX) Names Olivier Danos, Ph.D as Chief Scientific OfficerStreetInsider.com |
McGill Tribune |
What’s the deal with CRISPR?
McGill Tribune CRISPR offers the potential to cure presently untreatable cancers and diseases. Moreover, it could revive an extinct organism, such as the mammoth, using tiny bits of genomic information that scientists have collected through their serendipitous … European Patent Office to Grant Broad Claims on Patent Covering CRISPR-Cas9 Gene Editing TechnologyBusiness Wire (press release) |